The only way “next generation” primary care models can be profitable is by selling ancillary services to patients, like pharmaceuticals.
View in browser
Counterpoint logo with tagline underneath on a green gradient background

FOR YOUR CONSIDERATION

Understanding the Funny Math of Value-Based Primary Care Clinics 

Much has been written in the last five years about “reimagining primary care,” mostly by people who have never operated a primary care physician practice. Experienced operators know that the margins for the most efficient primary care practice are in the single digits; most health systems lose at least $100K per year per employed physician, hoping desperately to “make it up in volume,” i.e., downstream referrals. 

 

As we have written previously, “value-based primary care” is a reimbursement scheme that can be extraordinarily profitable under the following immutable conditions: the practice takes full capitation, for at least 50,000 “covered lives” in a metropolitan area, like Miami-Dade County or Las Vegas, from a single payer, preferably a Medicare Advantage plan, like Humana or United. Physician-led primary care practices like HealthCare Partners, MCCI and WellMed have executed this model expertly for decades. 

 

Why, then, have leading U.S. venture capital firms recently pursued a business model for their “holistic, consumer-centric, next-generation” primary care models that is almost completely opposite of this proven formula? To be fair, these venture capital firms can legitimately claim to have “reimagined” primary care; never before has a primary care strategy lost hundreds of millions of dollars. 

Chart showing recently reported information for large retailers'

1. Q2 2023 CVS earnings call (https://www.fool.com/earnings/call-transcripts/2023/08/02/cvs-health-cvs-q2-2023-earnings-call-transcript/) 

2. Through 3Q May 31, 2023 (PowerPoint Presentation (q4cdn.com)) 

3. Year ended December 31, 2022 One Medical Announces Results for Fourth Quarter and Full (globenewswire.com) 

Even more curious is why retailers with no previous experience in operating primary care practices have become the “go-to” exit strategy for these “next-generation” venture-backed companies losing hundreds of millions of dollars delivering “holistic” and “consumer-centric” primary care, often in a closet-like space in a pharmacy or over an iPhone.  

 

Anyone who has ever operated a primary care practice knows that there are two ways to be profitable:  

  1. take full capitation for as many patients as possible, and then control referrals for ancillary services as much as possible;  
  2. provide as many in-office ancillary services as possible, and then make as many self-referrals as the Stark Law allows.  

How could any board of directors approve paying any purchase price, much less billions, for a “next generation” primary care business model that is clearly financially unsustainable on a standalone basis, just like most primary care physician practices? (Editor's note: This was written prior to the news of the resignation of Rosalind Brewer from Walgreens on September 1, 2023.) The implicit size of the patient panel in these “next generation” primary care practices is one clinic per 1,700 patients, suggesting that the United States only needs 193,705 more of these “holistic, consumer-centric” clinics to meet the needs of every American. That, of course, is absurd, which is why that must not be the plan. If it were, then the already severe shortage of primary care physicians would increase by ~25% since a typical primary care patient panel is 2,300.1 

 

Why have Amazon, CVS and Walgreens invested billions of dollars to acquire enterprises that reliably lose hundreds of millions of dollars per year? What do the world’s largest retailers – the truly consumer-centric companies – know that the rest of the health economy doesn’t know?  

 

In a word, pharmacy. 

 

According to the Drug Channels Institute, total pharmacy industry prescription revenues were $547.9B in 2022, which is almost 50% of total U.S. hospital spending.2 The $1.3T in hospital spending in 2021 was divided among more than 5,000 hospitals, with HCA, the largest hospital operator, leading the market with a 4.4% share. In comparison, CVS had a 25.6% share of the prescription revenue segment in 2022, and the five largest U.S. pharmacy operators – CVS, Walgreens, Cigna, UnitedHealth Group and Walmart – had an aggregate 63.6% share. 

 

The only way that these “next generation” primary care models can be profitable is by selling ancillary services to patients, in this case, pharmaceuticals. 

 

The large retailers know that the Stark Law doesn’t prevent their “holistic, consumer-centric” clinics from prescribing pharmaceuticals to their patients and offering convenient delivery, whether a few steps down the store aisle or directly to the patient’s home. These retailers also know what other goods – cosmetics, toys, grocery items, etc. – their customers add to their shopping basket before checking out. 

 

What does that mean for traditional healthcare providers?  

 

What health systems consider fragmentation of primary care for “their” patients is what retailers believe is disintermediation on behalf of “their” customers. Merriam-Webster defines disintermediation as “the elimination of an intermediary in a transaction between two parties.”3  

 

Since disintermediation only happens when there is a transaction between a buyer and a seller, large retailers can only disintermediate healthcare with respect to the goods and services that they provide; however, they want to do that 100% of the time. Amazon, CVS, Walgreens and Walmart are without peer at winning the hearts and minds of the consumers in transactional settings, particularly for commodity goods and services. Of those retailers, Amazon is particularly effective in eliminating any friction between it and “its” customer for any service or good that it provides. 

 

Consequently, these retailers have no incentives for – or experience in – “care coordination” with respect to services that they don’t offer. For example, One Medical had 836,000 “members” at December 31, 2022, but only 40,000  – or less than 5% – were “at-risk.” Translation: One Medical has no financial interest in “care coordination” for the 796,000 members who are not “at-risk,” although they have an obvious interest in having Amazon Pharmacy deliver every single prescription written by a One Medical provider. 

 

On the margin, the incentives of large retailers are for their employed providers to order therapeutics over diagnostics, unless those diagnostics might result in a therapeutic. In turn, these retailers are – at least for now – indifferent to the “winner” of the referrals for those diagnostic and procedural transactions they don’t provide.  

 

Finally, the “membership” aspect of these “consumer-centric” primary care models is structurally transactional, not longitudinal. By openly advertising the price for a primary care or virtual visit, these retailers will increasingly commoditize what has historically been a relationship-driven – and price insensitive – business model. The implications for traditional primary care providers specifically and care coordination generally are momentous. 

Hal Andrews signature_first name

Hal Andrews, President & CEO, Trilliant Health

BY THE NUMBERS

The health plan price transparency rates under CMS’s Transparency in Coverage initiative reveal unique insights, particularly the wide variance in negotiated rates paid by different health plans – and even by the same health plan – for the same service in the same market.  

Chart showing professional outpatient medical group rates including Anthem Blue Cross Blue Shield and UnitedHealthcare

CONNECTING DOTS

💉 The Upper East Side is one of New York City’s wealthiest and healthiest neighborhoods, with some of the lowest rates of diabetes and obesity in the city. But last year, about 2.3% of the people living there were taking injectable medications belonging to a new class of weight loss and diabetes drugs – the highest rate in New York City. In comparison, those living in predominantly minority neighborhoods are not receiving medications like Ozempic, Wegovy or Monjaro for weight loss at the same rate, despite being disproportionally affected by obesity. Read our latest analysis on the use of GLP-1 drugs in NYC in The New York Times. 

 

📱 In February 2022, we published research recommending that health economy stakeholders should prepare for the implications of reduced telehealth market yield and the potential of its TAM nearing $0. Today, this outcome seems increasingly likely. Recently, UnitedHealthcare has decided to offer its low-acuity telehealth service at $0 to certain fully insured plans, while Walmart has reduced the price per virtual visit from $67 to $49, which will likely force other retail providers to respond. Read our latest analysis on telehealth’s total addressable market in The Compass.

 

🤝 In addition to understanding market dynamics and service mix, competitive and financial metrics are critical to informed health system M&A decision-making. The more similar hospitals are based on markets, services, financial and competitive metrics, the higher the probability that the merged system will continue with the established "playbook" and fully integrate. The more dissimilar these hospitals are, the more likely it is that systems will have greater difficulty fully integrating. Becker’s Healthcare uses our SimilarityEngine™ to explore 12 transactions announced or pursued in 2023. 

 

💻 As GLP-1 medications, like Wegovy and Ozempic, increase in popularity, the number of online outlets providing those medications has dramatically increased. Of the 3.6 million people with a new GLP-1 prescription in 2022, only 53% of people had a medical visit claim within three days. This data suggests that the remaining people with prescriptions – about 1.7 million Americans – likely filled their prescriptions through a non-traditional provider. Our Director of Research explains where patients are getting their GLP-1 prescriptions in STAT.

POINTS TO PONDER

→ Forecasting inflation lies at the heart of economic decision-making, but it is difficult to accurately estimate due to its reliance on the individual actions of the most notoriously unpredictable species – humans. However, a team of researchers used Google PaLM, a Large Language Model (LLMs), to construct retrospective inflation forecasts and found that LLM’s forecast have lower mean-squared errors overall in most years compared to the Survey of Professional Forecasters (SPF) and actual inflation data. (Federal Reserve Bank of St. Louis) 

 

→ Rural regions like Alaska, Wyoming, Nebraska and the Dakotas are the top five states for physician pay, despite not being high-earning states overall (Alaska is the exception). They're also not high-cost states, which makes it even more unusual to see those doctors out-earn their peers located in high-income areas. One of the most obvious answers for this trend is low competition. Due to the small supply of doctors in these states, they can charge more for everything because demand is high. Another less obvious answer is government influence. (The Washington Post) 

Interested in reading our other publications? Sign up here.

STRATEGIC INSIGHTS

RESEARCH

CONTACT US

LinkedIn
Twitter

Trilliant Health, 2 Maryland Farms, Ste 200, Brentwood, TN 37027

Manage preferences